Despite hopes raised by earlier observational studies and biomarker shifts, The Lancet trials found that oral semaglutide did not meaningfully slow clinical progression in early Alzheimer’s disease over two years.
Read it HERE
Advancing Alzheimer Detection in Down Syndrome
Down syndrome represents one of the most well-established genetic risk factors for early-onset Alzheimer disease (AD), with nearly all individuals developing Alzheimer-related neuropathology by midlife. Despite this predictable biological trajectory, variability in clinical presentation, timing of cognitive decline, and comorbid neurologic conditions continues to pose challenges for clinicians managing this population.
Read it all HERE
To reduce Alzheimer’s risk, focus on overall health
Researchers across USC are studying how lifestyle and environment influence dementia risk and resilience. They’re finding that what’s good for the body is also good for the brain.
Read more about it HERE
Genetic risk for Alzheimer’s disease may be modified by higher meat intake
Older people with a genetic risk of Alzheimer’s disease did not experience the expected increase in cognitive decline and dementia risk if they consumed relatively large amounts of meat. This is shown in a new study from Karolinska Institutet published in JAMA Network Open. The results may contribute to the development of more individually tailored dietary advice.
Read more about it HERE
An Alzheimer’s Revolution Is Coming, Experts Say
An earlier diagnosis and intervention strategy for Alzheimer’s disease is on the horizon, signaling a need to overhaul current detection methods and patient care protocols, experts at the Alzheimer’s Association Research Roundtable (AARR) said.
“Advances in biomarker technology, digital cognitive assessments, and amyloid-targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer’s disease,” reported Christopher Weber, PhD, of the Alzheimer’s Association in Chicago, and co-authors in Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
These advances create new possibilities to intervene before the onset of cognitive impairment, Weber and colleagues wrote. Targeting the earliest stages of Alzheimer’s, Weber said, “is similar to how doctors treat other diseases like heart disease and some cancers, where early detection and prevention are key parts of care.”
Read more HERE
New research shows how to diagnose people with Alzheimer’s plus a hard-to-identify dementia type
People with Alzheimer’s disease often have other neurodegenerative conditions as well, including a less-understood disorder called frontotemporal lobar degeneration (FTLD). While a precise diagnosis of FTLD has only been possible during an autopsy, new research shows how clinicians may be able to diagnose people living with both Alzheimer’s and FTLD by evaluating neuropsychiatric symptoms.
In a study published in Neurology, researchers found that compared to patients who have either of the two types of dementia alone, having both Alzheimer’s disease and FTLD is associated with greater likelihood of having known neuropsychiatric symptoms of both diseases.
The findings could have important implications for patients and their caregivers, the researchers noted, because patients with both disorders may experience a more complex disease course, rapid decline or unique responses to disease-modifying treatments.
Read more HERE